By Danielle Ramo, PhD—Marijuana use among young adult smokers is an increasingly prevalent problem, and clinicians who work with smokers need to find ways to incorporate multiple substance use into their patients’ treatment plans. [More]
(See video at the end of this post of Deborah Schrag, ME, MPH, from the Dana-Farber Cancer Institute, talking about the implications of the study.)
Adding bevacizumab to the standard chemotherapy regimen for non–small cell lung cancer (NSCLC)—an approach approved by the FDA in 2006—did not lead to significantly increased survival rates for patients older than 65 enrolled in Medicare, according to the results of a new study by researchers from Dana-Farber Cancer Institute, Boston, published in the April 18 JAMA.
In a previous trial, adding bevacizumab to the standard carboplatin-paclitaxel treatment for NSCLC improved survival in many patients with advanced disease, but not those in the 65 and older age range. Based on the new findings, the study authors recommended that bevacizumab not be automatically administered together with carboplatin-paclitaxel for older patients with NSCLC. They also suggested that physicians exercise caution in making treatment recommendations and use bevacizumab judiciously. [More]
By Todd W. Rice, MD
As we reported in Pulmonary Reviews, Todd W. Rice, MD, from Vanderbilt University School of Medicine, Nashville, and colleagues from the NIH ARDS Network conducted the EDEN trial—a randomized multicenter trial of 1,000 patients with acute lung injury—to determine if either trophic or full enteral feeding would reduce ventilator-free days or mortality. This research was presented at the Society of Critical Care Medicine’s 41st Critical Care Congress and also published in the February 22 JAMA. Rice elaborated on the study in his commentary below. (You can also listen to his audiocast.) Please weigh in with your opinion on the topic in the comments.
Mechanically ventilated patients are unable to provide for their own nutrition. Consequently, they are provided artificial nutrition, often in the form of enteral feeds. However, the optimal amount of enteral feeding to provide patients remains unknown, especially early in the critical illness. [More]
Audiocast By Timothy R. Aksamit, MD
Earlier this year, the COPD Foundation expanded its Bronchiectasis Research Registry to include patients with nontuberculous Mycobacteria (NTM), an often misdiagnosed orphan disease that can cause severe lung infections that mimic tuberculosis when certain individuals are exposed to soil and water.
According to John W. Walsh, President of the COPD Foundation, “NTM lung disease is a devastating illness that is challenging to treat. For unknown reasons, a once productive individual struck with NTM is often left with permanent lung damage and recurring illness, including loss of hearing and vision.”
According to John W. Walsh, President of the COPD Foundation, “NTM lung disease is a devastating illness that is challenging to treat. For unknown reasons, a once productive individual struck with NTM is often left with permanent lung damage and recurring illness, including loss of hearing and vision.” [More]